Daiichi Sankyo announces 5-year business plan; names R&D chief

Japanese pharma major Daiichi Sankyo (TYO: 4568) this week announced its five-year business plan for the fiscal period 2016-2020.

Daiichi Sankyo aspires to be a “Global Pharma Innovator with Competitive Advantage in Oncology” as its 2025 Vision by positioning its innovative pharmaceutical business, centered on oncology, as a core business in order to become a global company developing and

To overcome the patent cliff of the antihypertensive Benicar (olmesartan), one of the firm’s main products, it will make efforts for revenue recovery and profit generation, aiming at revenue of 940 billion yen ($7.83 billion) and operating profit of 100 billion yen in FY 2017. For 2020 it is targeting revenue of 1,200 billion yen and operating profit of 165 billion yen. The five-year plan calls for spending of 500 billion yen on M&A deals and the development of new fields of business like oncology.